Cargando…
Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis
BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 ye...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052070/ https://www.ncbi.nlm.nih.gov/pubmed/35582655 http://dx.doi.org/10.5306/wjco.v13.i4.287 |
_version_ | 1784696706513764352 |
---|---|
author | Perrin, Justine Farid, Karim Van Parijs, Hilde Gorobets, Olena Vinh-Hung, Vincent Nguyen, Nam P Djassemi, Navid De Ridder, Mark Everaert, Hendrik |
author_facet | Perrin, Justine Farid, Karim Van Parijs, Hilde Gorobets, Olena Vinh-Hung, Vincent Nguyen, Nam P Djassemi, Navid De Ridder, Mark Everaert, Hendrik |
author_sort | Perrin, Justine |
collection | PubMed |
description | BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 years. METHODS: We performed a retrospective search of the Universitair Ziekenhuis Brussel patient database for nonmetastatic patients who underwent preoperative PET between 2002-2008. PET positivity was determined by anatomical region of interest (AROI) findings for breast and axillary, sternal, and distant sites. The prognostic role of PET was examined as a qualitative binary factor (positive vs negative status) and as a continuous variable [maximum standard uptake value (SUVmax)] in multivariate survival analyses using Cox proportional hazards models. Among the 104 identified patients who received PET, 36 were further analyzed for the SUVmax in the AROI. RESULTS: Poor OS within the 15-year study period was predicted by PET-positive status for axillary (P = 0.033), sternal (P = 0.033), and combined PET-axillary/sternal (P = 0.008) nodes. Poor disease-free survival was associated with PET-positive axillary status (P = 0.040) and combined axillary/sternal status (P = 0.023). Cox models confirmed the long-term prognostic value of combined PET-axillary/sternal status [hazard ratio (HR): 3.08, 95% confidence interval: 1.42-6.69]. SUVmax of ipsilateral breast and axilla as continuous covariates were significant predictors of long-term OS with HRs of 1.25 (P = 0.048) and 1.54 (P = 0.029), corresponding to relative increase in the risk of death of 25% and 54% per SUVmax unit, respectively. In addition, the ratio of the ipsilateral axillary SUVmax over the contralateral axillary SUVmax was the most significant OS predictor (P = 0.027), with 1.94 HR, indicating a two-fold relative increase of mortality risk. CONCLUSION: Preoperative PET is valuable for prediction of long-term survival. Ipsilateral axillary SUVmax ratio over the uninvolved side represents a new prognostic finding that warrants further investigation. |
format | Online Article Text |
id | pubmed-9052070 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-90520702022-05-16 Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis Perrin, Justine Farid, Karim Van Parijs, Hilde Gorobets, Olena Vinh-Hung, Vincent Nguyen, Nam P Djassemi, Navid De Ridder, Mark Everaert, Hendrik World J Clin Oncol Retrospective Study BACKGROUND: The prognostic value of preoperative fluorine-18-fluorodeoxyglucose positron-emission tomography ((18)F-FDG PET) scan for determining overall survival (OS) in breast cancer (BC) patients is controversial. AIM: To evaluate the OS predictive value of preoperative PET positivity after 15 years. METHODS: We performed a retrospective search of the Universitair Ziekenhuis Brussel patient database for nonmetastatic patients who underwent preoperative PET between 2002-2008. PET positivity was determined by anatomical region of interest (AROI) findings for breast and axillary, sternal, and distant sites. The prognostic role of PET was examined as a qualitative binary factor (positive vs negative status) and as a continuous variable [maximum standard uptake value (SUVmax)] in multivariate survival analyses using Cox proportional hazards models. Among the 104 identified patients who received PET, 36 were further analyzed for the SUVmax in the AROI. RESULTS: Poor OS within the 15-year study period was predicted by PET-positive status for axillary (P = 0.033), sternal (P = 0.033), and combined PET-axillary/sternal (P = 0.008) nodes. Poor disease-free survival was associated with PET-positive axillary status (P = 0.040) and combined axillary/sternal status (P = 0.023). Cox models confirmed the long-term prognostic value of combined PET-axillary/sternal status [hazard ratio (HR): 3.08, 95% confidence interval: 1.42-6.69]. SUVmax of ipsilateral breast and axilla as continuous covariates were significant predictors of long-term OS with HRs of 1.25 (P = 0.048) and 1.54 (P = 0.029), corresponding to relative increase in the risk of death of 25% and 54% per SUVmax unit, respectively. In addition, the ratio of the ipsilateral axillary SUVmax over the contralateral axillary SUVmax was the most significant OS predictor (P = 0.027), with 1.94 HR, indicating a two-fold relative increase of mortality risk. CONCLUSION: Preoperative PET is valuable for prediction of long-term survival. Ipsilateral axillary SUVmax ratio over the uninvolved side represents a new prognostic finding that warrants further investigation. Baishideng Publishing Group Inc 2022-04-24 2022-04-24 /pmc/articles/PMC9052070/ /pubmed/35582655 http://dx.doi.org/10.5306/wjco.v13.i4.287 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Retrospective Study Perrin, Justine Farid, Karim Van Parijs, Hilde Gorobets, Olena Vinh-Hung, Vincent Nguyen, Nam P Djassemi, Navid De Ridder, Mark Everaert, Hendrik Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title | Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title_full | Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title_fullStr | Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title_full_unstemmed | Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title_short | Is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? A 15-year overall survival analysis |
title_sort | is there utility for fluorine-18-fluorodeoxyglucose positron-emission tomography scan before surgery in breast cancer? a 15-year overall survival analysis |
topic | Retrospective Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9052070/ https://www.ncbi.nlm.nih.gov/pubmed/35582655 http://dx.doi.org/10.5306/wjco.v13.i4.287 |
work_keys_str_mv | AT perrinjustine isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT faridkarim isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT vanparijshilde isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT gorobetsolena isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT vinhhungvincent isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT nguyennamp isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT djasseminavid isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT deriddermark isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis AT everaerthendrik isthereutilityforfluorine18fluorodeoxyglucosepositronemissiontomographyscanbeforesurgeryinbreastcancera15yearoverallsurvivalanalysis |